SRPT

SEC Filing Summary: AVI BioPharma, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for AVI BioPharma, Inc., a development-stage biopharmaceutical company, for the period ended September 30, 2004. The company focuses on the research and development of cancer vaccines, antisense, and drug delivery products. As of the reporting date, the company has not generated material revenue from product sales and has incurred an accumulated deficit of approximately $151 million since its inception in 1980.

Key Financial Metrics

Cash Flow (Nine Months Ended Sep 30, 2004):

• Net cash used in operating activities: $(20,348,533)
• Net cash provided by investing activities: $13,126,130 (primarily from sale of marketable securities)
• Net cash provided by financing activities: $7,039,337 (primarily from warrant exercises)

Material Changes vs. Prior Period

• Revenue Decline: Revenues dropped significantly to $9,151 in Q3 2004 from $414,352 in Q3 2003. For the nine-month period, revenue fell to $144,873 from $834,685, driven by decreases in grants and research contract income.
• Increased Operating Expenses: Total operating expenses rose to $20.25 million for the nine months ended Sep 30, 2004, compared to $12.55 million in the prior year period. This increase was primarily due to Research and Development (R&D) costs rising to $16.93 million from $8.88 million.
• R&D Drivers: Approximately $6.5 million of the nine-month R&D increase was attributed to contracting for the production of Good Manufacturing Practice (GMP) subunits for clinical trials. Management expects these specific expenditures to decrease in the remainder of 2004.
• General and Administrative (G&A): G&A expenses decreased to $3.32 million for the nine months ended Sep 30, 2004, down from $3.67 million in the prior year.

Guidance, Outlook, and Risks

• Liquidity Outlook: The company believes it has sufficient cash to fund operations through 2005. It expects 2004 operating expenditures to be approximately $23 million to $25 million. Expenditures for 2005 are expected to be equal to or greater than 2004 estimates.
• Future Funding: The company will need to raise additional capital to fund operations beyond 2005. It has no credit facility and does not intend to seek one. In Q3 2004, the company was informed of a potential $5 million government funding allocation for fiscal year 2005, though these funds have not yet been received.
• Recent Financing: In January 2004, institutional investors exercised warrants for 1,623,377 shares at $4.62 per share, generating net proceeds of $6.96 million. New five-year warrants were also issued to these investors.
• Risks: The company faces significant risks regarding the success of product development, regulatory approvals, and the ability to secure future financing. There is no assurance that the company will ever achieve profitability or generate material product revenues.

Key Facts for Investor Verification

• Verify the status and expected receipt of the $5 million government funding allocation mentioned for fiscal year 2005.
• Monitor the burn rate of cash and short-term securities against the projected $23-$25 million expenditure for the remainder of 2004.
• Confirm the progress of clinical trials utilizing the GMP subunits produced in the first nine months of 2004.
• Review the terms and exercise status of the new five-year warrants issued to institutional investors in January 2004.
• Assess the timeline for potential future equity offerings required to fund operations beyond 2005.